

Report on twinning short visit within the WP1 Task 1.11 of BASTION project

Science | Business, 16-18 Feb 2015, Brussels

Karolina Dzwonek

Jakub Golab

Jakub Golab, BASTION project coordinator and **Karolina Dzwonek**, Innovation Manager, during their short visit at Science|Business in February discussed current issues concerning MUW-Science|Business collaboration.



Karolina Dzwonek at the entrance to Science|Business office

Together with Science|Business management they discussed the remaining project tasks of Science|Business experts. It appeared that there was a need to modify the tasks of Ms Gail Edmondson so BASTION team members proposed the following amendment to the contract signed on 28-05-2013 by and between the Medical University of Warsaw, and Ms Gail Edmondson:

“**Subtask 1**(15 working days in total) is being changed into: preparation of guidelines for Medical University of Warsaw for efficient technology transfer and IP management, based on KULeuven and university’s technology transfer office - KU Leuven Research & Development (LRD) history and best practices.

The expert will take an interview with the Rector of KULeuven and one of the leaders of the LRD in order to identify strategies, solutions and management schemes that could be implemented by MUW authorities in order to facilitate translational research at the university. These guidelines could be used by MUW authorities in setting up the technology transfer unit within the structure of the university, financing it at the beginning of its activity, engaging the right human resources, building relations (inside the university and outside - identifying key partners).

The expert will present a case study of successful commercialization of a technology developed at KULeuven, pointing key success factors of the enterprise.

The new subtask 1 will be submitted in a form of a report, that includes two interviews, the summary of KULeuven technology transfer experience, guidelines for MUW authorities and a case study.”

During the meeting BASTION team members discussed with Science|Business upcoming event – Pharma Day 2015, to be organized within WP5 in the Spring 2015. The following list of participants was proposed:

1. Andrzej Bialkowski-Miler, BM Consulting
2. Marta Borkowska, Oncoarendi Therapeutics
3. Bruno Botta Sapienza, University of Rome
4. Krzysztof Brzozka, Selvita
5. Janusz Bujnicki, International Institute of Molecular and Cellular Biology

6. Agnieszka Byszek, Cancer Center and Institute of Oncology
7. Magdalena Chechlińska, Cancer Center and Institute of Oncology
8. Tomasz Ciach, Warsaw University of Technology
9. Marcin Ciuk, Nencki Institute of Experimental Biology
10. Bruce Conway, Rockefeller University
11. Iwona Cymerman, Nanovelos
12. Wojciech Czardybon, Selvita
13. Anna Czarnecka, Military Institute of Medicine
14. Janusz Debski, Institute of Biochemistry and Biophysics
15. Ewa Debudaj, Medical University of Warsaw BASTION
16. Iwona Drozdowska, Medical University of Warsaw BASTION
17. Andrzej Dziembowski, Institute of Biochemistry and Biophysics
18. Artur Dzwonek, Medical University of Warsaw
19. Karolina Dzwonek, Medical University of Warsaw BASTION
20. Anna Fogler, Medical University of Warsaw BASTION
21. Zbigniew Gaciong, Medical University of Warsaw BASTION
22. Paweł Gaj, Medical University of Warsaw BASTION
23. Jakub Golab, Medical University of Warsaw BASTION
24. Leszek Grabarczyk, National Center for Research and Development
25. Sławomir Gruca, Medical University of Warsaw BASTION
26. Henryk Gruza, FDFPHARMA
27. Duncan Holmes, GlaxoSmithKline
28. Magdalena Janczewska, Warsaw University of Technology
29. Radosław Jazwicz, Institute of Biochemistry and Biophysics
30. Przemysław Juszczyński, Institute of Hematology and Transfusion Medicine
31. Bożena Kamińska, Nencki Institute of Experimental Biology
32. Piotr Kamiński, Kamiński & Partners Patent and Trademark Attorneys
33. Joanna Kinasiewicz, Institute of Biocybernetics and Biomedical Engineering
34. Małgorzata Kolodziejczyk-Mierzynska, Medical University of Warsaw
35. Michał Konieczny, Merck
36. Tomasz Korkosz, Pfizer
37. Magdalena Kowalewska, Medical University of Warsaw
38. Katarzyna Koziak, Medical University of Warsaw
39. Magdalena Krol, Medical University of Warsaw BASTION
40. Leszek Krolicki, Medical University of Warsaw
41. Olga Krylova, Pfizer
42. Adam Krzystyniak, Nencki Institute of Experimental Biology
43. Aleksandra Kulikowska, Warsaw University of Technology
44. Andrzej Kusmierz, Idea2Business
45. Monika Lamparska-Przybysz, Polpharma SA
46. Joanna Lipner
47. Piotr Lutostanski, Echo Investments
48. Iwona Lugowska, Cancer Center and Institute of Oncology
49. Sławomir Majewski, Medical University of Warsaw BASTION
50. Marcin Makowski, Astra Zeneca
51. Marcin Mazurkiewicz, Nencki Institute of Experimental Biology

52. Shane McCollam, Science|Business
53. Danuta Mossakowska, GlaxoSmithKline
54. Karolina Niewiadomska, Warsaw City Hall
55. Dominika Nowis, Medical University of Warsaw BASTION
56. Marcin Nowotny, International Institute of Molecular and Cellular Biology
57. Jerzy Pieczykolan
58. Stanislaw Pikul, Oncoarendi Therapeutics
59. Paulina Podszywałow-Bartnicka, Nencki Institute of Experimental Biology
60. Ewa RutkowskaKieszkowska, RutkowskaKolasiński
61. Izabela Rzepczynska, National Center for Research and Development
62. Janusz Siedlecki, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
63. Piotr Sklepkiwicz, Oncoarendi Therapeutics
64. DariuszSmolen, BioTechMed cluster
65. Agata Stefanek, Warsaw University of Technology
66. Filip Stefaniak, International Institute of Molecular and Cellular Biology
67. Tomasz Stokłosa, Medical University of Warsaw BASTION
68. Robert Swider, Medical University of Warsaw
69. Marcin Szumowski, Oncoarendi Therapeutics
70. Magdalena Tagowska, Patpol
71. Robert Verhagen, Helix Biopharma
72. Maciej Wierzbicki, BioTechMed cluster
73. Pawel Wisniewski, Inagen
74. Michal Wojasinski, Warsaw University of Technology
75. Agnieszka Zagozdzon, Oncoarendi Therapeutics
76. Radoslaw Zagozdzon, Medical University of Warsaw BASTION
77. Ewa Zalewska, Institute of Biocybernetics and Biomedical Engineering
78. Daria Zdzalik, International Institute of Molecular and Cellular Biology
79. Anna Zdziarska, Oncoarendi Therapeutics
80. Florin Zubascu, Science|Business
81. Aldona Zygmunt, Pfizer
82. Agnieszka Zebrowska, Patpol

Also the preliminary agenda of the event was discussed and the following draft was prepared:

Pharma Day preliminary program (April 24th)

Keynote: Bruce Conway - From drug discovery to market: case study from J&J

Science for drug discovery:

Prof. Jakub Golab (Medical University of Warsaw) – to talk about molecular targets for immunotherapy of cancer

prof. LeszekKrolicki (Medical University of Warsaw) & Prof. Ewa Zalewska (Institute of Biocybernetics and Biomedical Engineering) – about new imaging methods in cancer diagnosis and for monitoring

efficacy of treatment (and capabilities of new Centre for Integrated Structural and Functional Studies of the Central Nervous System)

Prof. Bruno Botta (Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma)
GlaB: The Reward for Perseverance

Prof. Andrzej Dziembowski (Institute of Biochemistry and Biophysics) – about synthetic lethality as a therapeutic approach in multiple myeloma treatment

dr Marcin Nowotny (International Institute of Molecular and Cellular Biology) – about crystallography in drug discovery

Short Discussion Panel

How to make industry - science collaboration in early stage drug discovery programs more productive?

Discussants: dr Bruce Conway, Selvita, Prof. Bruno Botta, dr Maciej Wierzbicki (BTM cluster)...

Innovative drug discovery programs in Poland:

dr Krzysztof Brzozka/dr Wojciech Czardybon (VP & CSO at Selvita) – about PIM/Flt3 dual inhibitor drug discovery program

dr Marcin Szumowski (CEO at OncoArendi Therapeutics) – about the model of collaboration with academia

dr Iwona Ługowska (Cancer Center and institute of Oncology) – about phase I clinical trials center with Adamed

Big Pharma and Academia collaboration model

Duncan Holmes (GSK Discovery Partnerships with Academia) – about DPAC program

Closing discussion panel:

Role of Academic researchers, small to midsize biotech and big pharma in translational drug discovery process in oncology.

Duncan Holmes (GSK), Polpharma, Astra Zeneca and any other potential pharmaceutical companies.